| Detected | Trial | Change |
|---|---|---|
| 2026-05-14 | NCT07376382 A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With… |
Enrollment increased: 450 -> 680 participants |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07406542 | A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive… | Recurrent or Metastatic Breast Cancer | Not Yet Recruiting |
| NCT07417735 | SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal… | Locally Advanced/Metastatic/Recurrent ESCC | Not Yet Recruiting |
| NCT07442565 | SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ | Non-Small Cell Lung Cancer | Not Yet Recruiting |
| NCT07376382 | A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With… | NSCLC | Not Yet Recruiting |
| Phase 1 | |||
| NCT05948865 | A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors | Cancer | Recruiting |